Candace H. Feldman

Candace H. Feldman

Auto-generated profile, based on publicly available information

Candace H. Feldman

Brigham and Women's Hospital Boston Massachusetts

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2012 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
CFCandace H. Feldman
Candace H. Feldman
LHLinda T. Hiraki
Linda T. Hiraki
JLJun Liu
Jun Liu
MFMichael A. Fischer
Michael A. Fischer
DSDaniel H. Solomon
Daniel H. Solomon
KCKaren H. Costenbader
Karen H. Costenbader
Objective: Systemic lupus erythematosus (SLE) and lupus nephritis (LN) disproportionately affect individuals who are members of racial/ethnic minority groups and individuals of lower socioeconomic status (SES). This study was undertaken to investigate the epidemiology and sociodemographics of SLE and LN in the low‐income US Medicaid population.Methods: We utilized Medicaid Analytic eXtract data, with billing claims from 47 states and Washington, DC, for 23.9 million individuals ages 18–65 years who were enrolled in Medicaid for >3 months in 2000–2004. Individuals with SLE (≥3 visits >30 days apart with an International Classification of Diseases, Ninth Revision [ICD‐9] code of 710.0) and with LN (≥2 visits with an ICD‐9 code for glomerulonephritis, proteinuria, or renal failure) were identified. We calculated SLE and LN prevalence and incidence, stratified by sociodemographic category, and adjusted for number of American College of Rheumatology (ACR) member rheumatologists in the state and SES using a validated composite of US Census variables.Results: We identified 34,339 individuals with SLE (prevalence 143.7 per 100,000) and 7,388 (21.5%) with LN (prevalence 30.9 per 100,000). SLE prevalence was 6 times higher among women, nearly double in African American compared to white women, and highest in the US South. LN prevalence was higher among all racial/ethnic minority groups compared to whites. The areas with lowest SES had the highest prevalence; areas with the fewest ACR rheumatologists had the lowest prevalence. SLE incidence was 23.2 per 100,000 person‐years and LN incidence was 6.9 per 100,000 person‐years, with similar sociodemographic trends.Conclusion: In this nationwide Medicaid population, there was sociodemographic variation in SLE and LN prevalence and incidence. Understanding the increased burden of SLE and its complications in this low‐income population has implications for resource allocation and access to subspecialty care.

13 March 2015 in Arthritis & Rheumatology
Verified
Journal Article
Open access
PDF file
CFCandace H. Feldman
Candace H. Feldman
LHLinda T. Hiraki
Linda T. Hiraki
WWWolfgang C. Winkelmayer
Wolfgang C. Winkelmayer
FMFrancisco M. Marty
Francisco M. Marty
JFJessica M. Franklin
Jessica M. Franklin
KCKaren H. Costenbader
Karen H. Costenbader
Objective: To examine the epidemiology of serious infections, a significant cause of morbidity and mortality in systemic lupus erythematosus (SLE), in a nationwide cohort of SLE and lupus nephritis (LN) patients.Methods: Using the Medicaid Analytic eXtract database for the years 2000–2006, we identified patients ages 18–64 years who had SLE and the subset who had LN. We ascertained cases of serious hospitalized infections using validated algorithms, and we determined 30‐day mortality rates. Poisson regression was used to calculate infection incidence rates and multivariable Cox proportional hazards models were used to calculate hazard ratios (HRs) for the first infection, adjusted for sociodemographic variables, medication use, and an SLE‐specific risk adjustment index.Results: We identified 33,565 patients with SLE, 7,113 of whom had LN. There were 9,078 serious infections in 5,078 SLE patients and 3,494 infections in 1,825 LN patients. The infection incidence rate per 100 person‐years was 10.8 in the SLE cohort and 23.9 in the LN subcohort. In adjusted models for the SLE cohort, we observed increased risks of infection in men as compared to women (HR 1.33 [95% confidence interval (95% CI) 1.20–1.47]), in blacks as compared to whites (HR 1.14 [95% CI 1.06–1.21]), and in users of glucocorticoids (HR 1.51 [95% CI 1.43–1.61]) and immunosuppressive drugs (HR 1.11 [95% CI 1.03–1.20]) as compared to never users. Hydroxychloroquine users had a reduced risk of infection as compared to never users (HR 0.73 [95% CI 0.68–0.77]). The 30‐day mortality rate per 1,000 person‐years among those hospitalized with infections was 21.4 in the SLE cohort and 38.6 in the LN subcohort.Conclusion: In this diverse, nationwide cohort of SLE patients, we observed a substantial burden of serious infections with many subsequent deaths, particularly among those with LN.

19 June 2015 in Arthritis Care & Research
Verified
Journal Article
Open access
PDF file
CFCandace H. Feldman
Candace H. Feldman
JYJinoos Yazdany
Jinoos Yazdany
HGHongshu Guan
Hongshu Guan
DSDaniel H. Solomon
Daniel H. Solomon
KCKaren H. Costenbader
Karen H. Costenbader
Objective: We examined whether nonadherence to hydroxychloroquine (HCQ) or immunosuppressive medications (ISMs) was associated with higher subsequent acute care utilization among Medicaid beneficiaries with systemic lupus erythematosus (SLE).Methods: We utilized US Medicaid data from 2000–2006 to identify adults ages 18–64 years with SLE who were new users of HCQ or ISMs. We defined the index date as receipt of HCQ or ISMs without use in the prior 6 months. We measured adherence using the medication possession ratio (MPR), the proportion of days covered by total days’ supply dispensed, for the 1‐year post‐index date. Our outcomes were all‐cause and SLE‐related emergency department (ED) visits and hospitalizations in the subsequent year. We used multivariable Poisson regression models to examine the association between nonadherence (MPR <80%) and acute care utilization, adjusting for sociodemographics and comorbidities.Results: We identified 9,600 HCQ new users and 3,829 ISM new users with SLE. The mean ± SD MPR for HCQ was 47.8% ± 30.3% and for ISMs was 42.7% ± 30.7%. Seventy‐nine percent of HCQ users and 83% of ISM users were nonadherent (MPR <80%). In multivariable models, among HCQ users, the incidence rate ratio (IRR) of ED visits was 1.55 (95% confidence interval [95% CI] 1.43–1.69) and the IRR of hospitalizations was 1.37 (95% CI 1.25–1.50), comparing nonadherers to adherers. For ISM users, the IRR of ED visits was 1.64 (95% CI 1.42–1.89) and of hospitalizations was 1.67 (95% CI 1.41–1.96) for nonadherers versus adherers.Conclusion: In this cohort, nonadherence to HCQ and ISMs was common and was associated with significantly higher subsequent acute care utilization.

7 February 2015 in BMC Musculoskeletal Disorders
Verified
Journal Article
Open access
PDF file
CFCandace H Feldman
Candace H Feldman
YDYan Dong
Yan Dong
JKJeffrey N Katz
Jeffrey N Katz
LDLaurel A Donnell-Fink
Laurel A Donnell-Fink
ELElena Losina
Elena Losina
Patients with higher socioeconomic status (SES) are shown to have better total knee arthroplasty (TKA) outcomes compared to those with lower SES. The relationship between SES and factors that influence TKA use is understudied. We examined the association between SES and pain, function and pain catastrophizing at presentation for TKA. In patients undergoing TKA at an academic center, we obtained preoperative pain and functional status (WOMAC Index 0–100, 100 worst), pain catastrophizing (PCS, ≥16 high), and mental health (MHI-5, <68 poor). We described individual-level SES using education as a proxy, and area-level SES using a validated composite index linking geocoded addresses to U.S. Census data. We measured associations between these indicators and pain, function and pain catastrophizing, adjusting for age, sex and BMI. Among 316 patients, mean age was 65.9 (SD 8.7), 59% were female, and 88% were Caucasian; 17% achieved less than college education and 62% were college graduates. The median area SES index score was 59 (U.S. median 51). Bivariable analyses demonstrated associations between higher individual- and area-level SES and lower pain, higher function and less pain catastrophizing (all p<0.05). Adjusted analyses demonstrated statistically significant associations between higher individual- and area-level SES and better function and less pain. In this cohort, patients with higher individual- and area-level SES had lower pain and higher function at the time of TKA than lower SES patients. Further research is needed to assess what constitutes appropriate levels of pain and function to undergo TKA in these higher SES groups.

1 October 2018 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Closed access
CFCandace H. Feldman
Candace H. Feldman
JCJamie Collins
Jamie Collins
ZZZhi Zhang
Zhi Zhang
SSS.V. Subramanian
S.V. Subramanian
DSDaniel H. Solomon
Daniel H. Solomon
KCKaren H. Costenbader
Karen H. Costenbader

2 September 2016 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
PDF file
CFCandace H. Feldman
Candace H. Feldman
FMFrancisco M. Marty
Francisco M. Marty
WWWolfgang C. Winkelmayer
Wolfgang C. Winkelmayer
HGHongshu Guan
Hongshu Guan
JFJessica M. Franklin
Jessica M. Franklin
SKSeoyoung C. Kim
Seoyoung C. Kim